retatrutide topical Triple Agonist (GLP-1/GIP/GCG) Retatrutide Guide: Triple Agonist Research
Description
Glucagon-like peptide-1 (GLP-1) agonists, employed to treat diabetes and obesity, has been tested on MASH patients and is widely regarded as the preferred treatment for MASH
Most insurers require documented evidence: BMI 30 or 27 with weight-related comorbidity, failed lifestyle interventions, or type 2 diabetes diagnosis
Hsu said
These might include dietary changes associated with weight loss, stress related to lifestyle modifications, concurrent medications, underlying mental health conditions, or other medical issues
Hydration requires attention throughout Retatrutide use
At Condrell Primary Care, we take a comprehensive approach to weight management
